Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 4
2002 37
2003 79
2004 135
2005 120
2006 59
2007 35
2008 34
2009 14
2010 24
2011 13
2012 21
2013 11
2014 9
2015 6
2016 8
2017 6
2018 4
2019 2
2020 2
2021 3
2022 2
2023 1
2024 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

610 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean mgximelagatran (1 results)?
Ximelagatran.
Choudhury A, Goyal D, Lip GY. Choudhury A, et al. Drugs Today (Barc). 2006 Jan;42(1):3-19. doi: 10.1358/dot.2006.42.1.893611. Drugs Today (Barc). 2006. PMID: 16511607 Review.
Double-blind trials have also revealed the efficacy of ximelagatran in the secondary prevention of venous thromboembolism and shown the agent to be as effective as enoxaparin/warfarin in treating patients with acute deep vein thrombosis. Adverse effects with ximelagatra …
Double-blind trials have also revealed the efficacy of ximelagatran in the secondary prevention of venous thromboembolism and shown t …
Ximelagatran: an oral direct thrombin inhibitor.
Dager WE, Vondracek TG, McIntosh BA, Nutescu EA. Dager WE, et al. Ann Pharmacother. 2004 Nov;38(11):1881-97. doi: 10.1345/aph.1E078. Epub 2004 Sep 21. Ann Pharmacother. 2004. PMID: 15383641 Review.
OBJECTIVE: To present the chemistry, pharmacology, and pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor (DTI), and to review available comparative clinical trial data evaluating its efficacy and safety relative to other antithrombotic agents in the preve …
OBJECTIVE: To present the chemistry, pharmacology, and pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor (DTI), and …
[Ximelagatran].
Nagata K. Nagata K. Nihon Rinsho. 2006 Oct 28;64 Suppl 7:630-6. Nihon Rinsho. 2006. PMID: 17461216 Review. Japanese. No abstract available.
Ximelagatran (AstraZeneca).
Hopfner R. Hopfner R. Curr Opin Investig Drugs. 2002 Feb;3(2):246-51. Curr Opin Investig Drugs. 2002. PMID: 12020054 Review.
By December 2000, a phase II trial was underway of ximelagatran as a potential treatment following myocardial infarction [395237]. In December 2001, early phase clinical trials were ongoing for post acute coronary syndrome [431673]. ...Exanta is the trade name for both mel …
By December 2000, a phase II trial was underway of ximelagatran as a potential treatment following myocardial infarction [395237]. In …
Ximelagatran: direct thrombin inhibitor.
Ho SJ, Brighton TA. Ho SJ, et al. Vasc Health Risk Manag. 2006;2(1):49-58. doi: 10.2147/vhrm.2006.2.1.49. Vasc Health Risk Manag. 2006. PMID: 17319469 Free PMC article. Review.
As an oral agent, ximelagatran has a number of desirable properties including a rapid onset of action, fixed dosing, stable absorption, apparent low potential for medication interactions, and no requirement for monitoring of drug levels or dose adjustment. ...Clinical stud …
As an oral agent, ximelagatran has a number of desirable properties including a rapid onset of action, fixed dosing, stable absorptio …
Ximelagatran: a new type of oral anticoagulant.
Kwok L, Molckovsky D, Boucher M. Kwok L, et al. Int J Technol Assess Health Care. 2005 Fall;21(4):480-6. doi: 10.1017/S026646230505066X. Int J Technol Assess Health Care. 2005. PMID: 16262971 Review.
Overall, ximelagatran's efficacy appears comparable to other anticoagulants in these clinical settings. Also, bleeding rates were generally similar between ximelagatran and comparators but, as for warfarin, bleeding risk increases with higher ximelagatran dos …
Overall, ximelagatran's efficacy appears comparable to other anticoagulants in these clinical settings. Also, bleeding rates were gen …
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC, Perry CM, Faulds D. Evans HC, et al. Drugs. 2004;64(6):649-78. doi: 10.2165/00003495-200464060-00010. Drugs. 2004. PMID: 15018597 Review.
The efficacy of subcutaneous melagatran followed by oral ximelagatran has been investigated in four European trials and the efficacy of an all oral ximelagatran regimen has been investigated in five US trials. ...However, ximelagatran 36 mg twice daily was su …
The efficacy of subcutaneous melagatran followed by oral ximelagatran has been investigated in four European trials and the efficacy …
Ximelagatran: the first oral direct thrombin inhibitor.
Crowther MA, Weitz JI. Crowther MA, et al. Expert Opin Investig Drugs. 2004 Apr;13(4):403-13. doi: 10.1517/13543784.13.4.403. Expert Opin Investig Drugs. 2004. PMID: 15102589 Review.
Since it produces a predictable anticoagulant response, ximelagatran does not require coagulation monitoring. Phase III clinical trials have evaluated the efficacy and safety of ximelagatran for the prevention and treatment of venous thromboembolism and for the prev …
Since it produces a predictable anticoagulant response, ximelagatran does not require coagulation monitoring. Phase III clinical tria …
Ximelagatran: an orally active direct thrombin inhibitor.
Gulseth MP. Gulseth MP. Am J Health Syst Pharm. 2005 Jul 15;62(14):1451-67. doi: 10.2146/ajhp040534. Am J Health Syst Pharm. 2005. PMID: 15998925 Review.
PURPOSE: The chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, contraindications, and adverse effects of ximelagatran are reviewed. SUMMARY: Ximelagatran is the first orally active direct thrombin inhibitor to be tested in Phas …
PURPOSE: The chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, contraindications, and adverse effects …
Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge?
Mousa SA, Abdel-Razeq HN. Mousa SA, et al. Cardiovasc Drug Rev. 2005 Winter;23(4):331-44. doi: 10.1111/j.1527-3466.2005.tb00176.x. Cardiovasc Drug Rev. 2005. PMID: 16614732 Review.
Multiple controlled, prospective trials compared ximelagatran with low molecular weight heparin or warfarin in prevention of venous thromboembolism in patients undergoing major orthopedic procedures. ...Ximelagatran has been approved, however, by the European regula …
Multiple controlled, prospective trials compared ximelagatran with low molecular weight heparin or warfarin in prevention of venous t …
610 results